In a tough funding environment, John Maraganore cautions against rushing into founding a company. He recommends that aspiring entrepreneurs first spend 5-10 years at a successful biotech. He argues that when capital is scarce, investors prioritize experienced operators, making deep industry experience a critical prerequisite for getting funded.

Mamoon Hamid advises against a direct path into venture capital. He argues the best training is working at a fast-growing startup to gain firsthand experience in building, shipping, and selling a product. This operational background develops the necessary empathy for founders, which is crucial for a successful VC career.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

The expectation for venture capitalists has shifted. Founders no longer just want finance professionals; they demand investors who have direct operational experience and have been "in the trenches" of building a company. This change reflects a move towards more hands-on, value-add investing.

Venture capital firm Sofinnova prioritizes hiring experienced pharma operators, even those with zero investment background. These experts provide invaluable hands-on guidance on drug development and commercialization to portfolio companies, contributing to a high rate of FDA product approvals.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Starting in business development at a large firm like Genentech provides a holistic understanding of the entire drug lifecycle—from discovery and regulation to clinical trials and marketing. This "full spectrum" view offers invaluable training for a future CEO.

Derek Adams began in late-stage vaccine manufacturing at Merck before moving to earlier-stage companies. This "reverse" path provides a deep understanding of commercial realities, operational execution, and scale-up challenges that is invaluable for building a capital-efficient startup from the ground up.

Many VC firms hire former operators for their expertise, but success isn't guaranteed. The best operator-VCs avoid the urge to "backseat drive" the companies they fund. Instead, they leverage their experience with extraordinary humility, acting as a supportive advisor rather than a replacement CEO.